Appeal No. 1996-1002
Application 07/988,945
Claim 18 is illustrative of the subject matter on appeal and reads as follows:
18. Antibody composition useful for inhibiting the binding of IL-2 to the high
affinity interleukin 2 receptor (IL-2R) comprising, a) a monoclonal antibody which
specifically binds to high affinity IL-2R " chain and inhibits binding of IL-2 thereto and
b) a monoclonal antibody which specifically binds to high affinity IL-2R $ chain and
inhibits binding of IL-2 thereto, wherein said monoclonal antibody which specifically
binds to said high affinity IL-2R $ chain is C68/41 (ECACC 90090704) or A23A41 (DSM
ACC2015).
The references relied upon by the examiner are:
Takeshita et al. (Takeshita), "Monoclonal Antibody Defining a Molecule Possibly
Identical to the p75 Subunit of Interleukin 2 Receptor," Journal of Experimental
Medicine, Vol. 169, pp. 1323-1332, 1989.
Kupiec-Weglinski et al. (Kupiec-Weglinski), "Selective Immunosuppression with Anti-
Interleukin 2 Receptor-Targeted Therapy: Helper and Suppressor Cell Activity in Rat
Recipients of Cardiac Allografts," European Journal of Immunology, Vol. 17, pp. 313-
319, 1987.
Williams, "Novel Antibody Reagents: Production and Potential," TibTech., Vol. 6, pp.
36-42, 1988.
Morrison et al. (Morrison), "Production and Characterization of Genetically Engineered
Antibody Molecules," Clinical Chemistry, Vol. 34(9), pp 1668-1675, 1988.
Queen et al. (Queen), "A Humanized Antibody that Binds to the Interleukin 2 Receptor,"
Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 10029-10033, 1989.
Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," Science, Vol. 252,
pp 1657-1662, 1991.
Hird et al. (Hird), "Immunotherapy with Monoclonal Antibodies," Genes and Cancer,
Eds. Carney and Sikora, John Wiley & Sons, Ltd., pp 183-189, 1990.
Harris et al. (Harris), "Therapeutic Antibodies the Coming of Age," TibTech., Vol. 11,
pp. 42-44, 1993.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007